CDE Clears IND Application for Therapeutic Candidate Targeting ATTR

LATESTNEWS

• Landmark Clinical Approval for YOLT-201 Obtained by the NMPA

  Mar 04, 2024

• Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies

  Feb 15, 2024

• First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

  Dec 17, 2023